CELC - Celcuity LLC

CELC - Celcuity LLC

https://www.celcuity.com

Buy Momentum: Bearish

Recent News

Powered by Alpha Vantage

Celcuity Announces Upsized Senior Secured Term Loan Facility of $500 Million with Innovatus Capital Partners and Oxford Finance - Celcuity ( NASDAQ:CELC )

Benzinga • 5 days, 19 hours ago • score: 0.16

MINNEAPOLIS, Sept. 09, 2025 ( GLOBE NEWSWIRE ) -- Celcuity Inc. ( "Celcuity" ) , a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it has entered into an amendment to its existing senior secured credit facility with an affiliate ...

Celcuity to Initiate NDA Submission of Gedatolisib in PIK3CA Wild-Type Cohort in HR+/HER2- Advanced Breast Cancer Under FDA's Real-Time Oncology Review Program - Celcuity ( NASDAQ:CELC )

Benzinga • 2 weeks, 4 days ago • score: 0.12

MINNEAPOLIS, Aug. 27, 2025 ( GLOBE NEWSWIRE ) -- Celcuity Inc. CELC, a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the U.S.

Celcuity Q2 Results Highlight Cash Surge

Motley Fool • 1 month ago • score: 0.38

Celcuity ( NASDAQ:CELC ) reported second quarter 2025 results on Aug. 14, 2025, highlighted by top-line Phase III data for gedatolisib in second-line HR-positive, HER2-negative advanced breast cancer. The company ended the quarter with $455 million in pro forma cash after raising $286.5 million ...

Celcuity Expenses Jump 81 Percent

Motley Fool • 1 month ago • score: 0.07

Celcuity ( NASDAQ:CELC ) , a clinical-stage biotechnology company developing targeted therapies for cancer, released its second quarter 2025 earnings on August 14, 2025. The highlight was topline Phase 3 data for lead drug gedatolisib, which showed unprecedented results in advanced breast cancer ...

Celcuity Inc. Schedules Release of Second Quarter 2025 Financial Results and Webcast/Conference Call

GlobeNewswire • 1 month, 1 week ago • score: -0.07

MINNEAPOLIS, Aug. 07, 2025 ( GLOBE NEWSWIRE ) -- Celcuity Inc. ( Nasdaq: CELC ) , a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the second quarter 2025 after the market closes on ...

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Range-Bound

As of 2025-09-10 (Snapshot)

Celcuity Inc., a clinical-stage biotechnology company, discovers cancer subtypes and therapeutic options for cancer patients in the United States. The company is headquartered in Minneapolis, Minnesota.

52W High

$57.48

52W Low

$7.58

MA Status:

50D: Above 200D: Above

Beta (~1 neutral, <0.9 lower risk)

0.73

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-7.80

EV/Revenue (<3 favorable)

N/A

P/S (TTM) (<3 favorable)

N/A

P/B (<3 favorable)

53.24

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

12.04%

Institutions (25–75% balanced)

83.64%

Shares Outstanding

42,426,700

Float

19,563,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

0

Gross Profit (TTM)

0

EPS (TTM)

-3.47

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-1.35%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Bearish momentum

Value

6.0975

Previous

6.1722

Trend

Falling

Signal Cross

No cross

As of

Sep. 05, 2025